SAN FRANCISCO, CA–(Marketwired – July 19, 2017) – In its corporate update for Q2/17, a Canada-based biotech targeting neurological disorders including Alzheimer’s disease informed investors of advancements in several programs, including designation of a second validated lead compound in development.
Included in this article is: ProMIS Neurosciences Inc. (TSE: PMN)
Among ProMIS Neurosciences Inc.’s “key accomplishments” in the quarter, the company noted it expanded its potentially “best in class amyloid-beta (Aβ) portfolio for Alzheimer’s disease,” according to a July 10 news release. In its oral presentation, the company stressed its emphasis on the “best in class” goal, noting that even though Biogen Inc.’s aducanumab will be “first in class” and is progressing well in development, the ProMIS compound could be more selective and possess greater patient benefits.
Advancements included designating “PMN350 as second validated product lead [based on] in vivo data and biologic evidence of neuronal protection against toxic Aβ oligomers,” as well as continuing efforts to validate “additional antibody product candidates against various Aβ epitope targets [with] data anticipated in coming months.”
Continue reading this article: Biotech with Alzheimer’s Focus Makes Progress on Several Fronts
About Streetwise Reports – The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
DISCLOSURES:
The following company mentioned in this article is a billboard sponsor of Streetwise Reports: ProMIS Neurosciences Inc. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
Please see the end of the article for the complete disclosures: Biotech with Alzheimer’s Focus Makes Progress on Several Fronts
Contact Information:
Carrie Beal Amaro
Associate Publisher
(Email contact
)
